BR112022019129A2 - Anticorpos de ligação a siglec15 e usos dos mesmos - Google Patents
Anticorpos de ligação a siglec15 e usos dos mesmosInfo
- Publication number
- BR112022019129A2 BR112022019129A2 BR112022019129A BR112022019129A BR112022019129A2 BR 112022019129 A2 BR112022019129 A2 BR 112022019129A2 BR 112022019129 A BR112022019129 A BR 112022019129A BR 112022019129 A BR112022019129 A BR 112022019129A BR 112022019129 A2 BR112022019129 A2 BR 112022019129A2
- Authority
- BR
- Brazil
- Prior art keywords
- antigen
- siglec15
- binding portion
- antibody
- binding antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063000566P | 2020-03-27 | 2020-03-27 | |
| PCT/CN2021/083194 WO2021190622A1 (en) | 2020-03-27 | 2021-03-26 | Antibodies binding siglec15 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022019129A2 true BR112022019129A2 (pt) | 2022-12-06 |
Family
ID=77891322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022019129A BR112022019129A2 (pt) | 2020-03-27 | 2021-03-26 | Anticorpos de ligação a siglec15 e usos dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11739147B2 (https=) |
| EP (1) | EP4126938A4 (https=) |
| JP (2) | JP7364315B2 (https=) |
| KR (1) | KR102651263B1 (https=) |
| CN (1) | CN115348970B (https=) |
| AU (2) | AU2021240769B2 (https=) |
| BR (1) | BR112022019129A2 (https=) |
| IL (1) | IL296736B2 (https=) |
| MX (1) | MX2022011951A (https=) |
| PH (1) | PH12022552520A1 (https=) |
| SA (1) | SA522440646B1 (https=) |
| WO (1) | WO2021190622A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022552520A1 (en) * | 2020-03-27 | 2023-01-04 | Biosion Inc | Antibodies binding siglec15 and uses thereof |
| TW202330617A (zh) * | 2021-11-25 | 2023-08-01 | 大陸商正大天晴藥業集團股份有限公司 | 抗Siglec-15抗體及其應用 |
| CN114134183B (zh) * | 2021-12-24 | 2022-12-06 | 广东南模生物科技有限公司 | 一种siglec15基因人源化动物模型的构建方法及应用 |
| CN114807052A (zh) * | 2022-06-07 | 2022-07-29 | 江苏亲科生物研究中心有限公司 | Siglec15单克隆抗体及其制备方法和用途 |
| KR20250023399A (ko) * | 2022-06-13 | 2025-02-18 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-siglec15 항체 및 이의 용도 |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2025247334A1 (en) * | 2024-05-30 | 2025-12-04 | Biosion Inc. | Recombinant fusion protein targeting siglec15 and gm-csfr |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4604184B2 (ja) * | 2005-07-12 | 2010-12-22 | 独立行政法人産業技術総合研究所 | 新規糖鎖認識蛋白質及びその遺伝子 |
| US8168181B2 (en) | 2006-02-13 | 2012-05-01 | Alethia Biotherapeutics, Inc. | Methods of impairing osteoclast differentiation using antibodies that bind siglec-15 |
| MX2013003828A (es) * | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Anticuerpo dirigido a la proteina lectina tipo inmunoglobulina de union a acido sialico-15 relacionada con osteoclastos. |
| CA2848074A1 (en) | 2011-09-09 | 2013-03-14 | Medimmune Limited | Anti-siglec-15 antibodies and uses thereof |
| BR112014024267A8 (pt) * | 2012-03-30 | 2017-07-25 | Daiichi Sankyo Co Ltd | anticorpo ou um fragmento de ligação de antígeno do anticorpo, composição farmacêutica, usos de pelo menos um dos anticorpos ou fragmentos de ligação de antígeno e de uma composição, polinucleotídeo, vetor, e, célula hospedeira transformada |
| HK1210192A1 (en) * | 2012-07-19 | 2016-04-15 | Alethia Biotherapeutics Inc. | Anti-siglec-15 antibodies |
| EP3157562A4 (en) * | 2014-06-18 | 2017-12-20 | Daiichi Sankyo Company, Limited | Anti-siglec-15 antibodies for use in treatment of osteogenesis imperfecta |
| AU2016354100B2 (en) | 2015-11-10 | 2023-11-30 | Yale University | Compositions and methods for treating autoimmune diseases and cancers |
| DK3515478T3 (da) * | 2016-09-21 | 2024-05-21 | Nextcure Inc | Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf |
| CN108250296B (zh) * | 2018-01-17 | 2020-07-07 | 长春金赛药业有限责任公司 | 全人源抗人pd-l1单克隆抗体及其应用 |
| JP7156653B2 (ja) * | 2018-08-30 | 2022-10-19 | イノベイティブ セルラー セラピューティクス ホールディングス，エルティディ | 固形腫瘍を治療するためのキメラ抗原受容体細胞 |
| PH12022552520A1 (en) * | 2020-03-27 | 2023-01-04 | Biosion Inc | Antibodies binding siglec15 and uses thereof |
-
2021
- 2021-03-26 PH PH1/2022/552520A patent/PH12022552520A1/en unknown
- 2021-03-26 CN CN202180024369.4A patent/CN115348970B/zh active Active
- 2021-03-26 BR BR112022019129A patent/BR112022019129A2/pt unknown
- 2021-03-26 IL IL296736A patent/IL296736B2/en unknown
- 2021-03-26 JP JP2022547787A patent/JP7364315B2/ja active Active
- 2021-03-26 AU AU2021240769A patent/AU2021240769B2/en active Active
- 2021-03-26 EP EP21774588.4A patent/EP4126938A4/en active Pending
- 2021-03-26 KR KR1020227030409A patent/KR102651263B1/ko active Active
- 2021-03-26 WO PCT/CN2021/083194 patent/WO2021190622A1/en not_active Ceased
- 2021-03-26 MX MX2022011951A patent/MX2022011951A/es unknown
-
2022
- 2022-09-25 SA SA522440646A patent/SA522440646B1/ar unknown
- 2022-09-27 US US17/935,815 patent/US11739147B2/en active Active
-
2023
- 2023-05-31 AU AU2023203397A patent/AU2023203397A1/en active Pending
- 2023-06-23 US US18/340,367 patent/US20240002508A1/en active Pending
- 2023-10-03 JP JP2023172391A patent/JP7827951B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20230106715A1 (en) | 2023-04-06 |
| AU2021240769A1 (en) | 2022-10-20 |
| JP7364315B2 (ja) | 2023-10-18 |
| CA3173201A1 (en) | 2021-09-30 |
| KR20220158696A (ko) | 2022-12-01 |
| CN115348970B (zh) | 2023-11-14 |
| EP4126938A4 (en) | 2024-04-10 |
| JP7827951B2 (ja) | 2026-03-11 |
| JP2023518153A (ja) | 2023-04-28 |
| JP2024016024A (ja) | 2024-02-06 |
| US11739147B2 (en) | 2023-08-29 |
| AU2023203397A1 (en) | 2023-06-29 |
| IL296736B2 (en) | 2025-04-01 |
| AU2021240769B2 (en) | 2023-04-06 |
| NZ792658A (en) | 2024-07-05 |
| CN115348970A (zh) | 2022-11-15 |
| US20240002508A1 (en) | 2024-01-04 |
| IL296736A (en) | 2022-11-01 |
| KR102651263B1 (ko) | 2024-03-25 |
| SA522440646B1 (ar) | 2024-08-29 |
| EP4126938A1 (en) | 2023-02-08 |
| PH12022552520A1 (en) | 2023-01-04 |
| WO2021190622A1 (en) | 2021-09-30 |
| MX2022011951A (es) | 2023-03-06 |
| IL296736B1 (en) | 2024-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022019129A2 (pt) | Anticorpos de ligação a siglec15 e usos dos mesmos | |
| BR112022017174A2 (pt) | Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor | |
| BR112021024553A2 (pt) | Molécula de ligação específica para cd73 e uso de molécula de ligação | |
| BR112023021426A2 (pt) | Anticorpos de ligação a trop2 e usos dos mesmos | |
| BR112019023992A2 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado | |
| BR112022012524A2 (pt) | Porção química de ligação que se liga especificamente a claudin18.2, polinucleotídeo, vetor, célula hospedeira, receptor de antígeno quimérico (car ), célula imune geneticamente modificada, composição farmacêutica, método de tratamento de um tumor ou câncer que expressa claudin18.2 | |
| BR112019008634A2 (pt) | anticorpos anti-pd-l1 e variantes | |
| CO2021006248A2 (es) | Anticuerpos anti-nkg2a y usos de los mismos | |
| BR112022020256A2 (pt) | anticorpo monoclonal ou um fragmento de ligação ao antígeno do mesmo, ácido nucleico, vetor de expressão, célula, composição, uso da composição e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
| BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
| CL2020001726A1 (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| BR112016016207A2 (pt) | Anticorpo anti-pd-l1 isolado ou fragmento de ligação ao antígeno do mesmo, seu método de produção, composição farmacêutica, molécula de polinucleotídeo isolada, vetor, célula, e uso dos mesmos | |
| BR112022015450A2 (pt) | Anticorpo monoclonal isolado ou fragmento de conexão ao antígeno dele, composição farmacêutica, ácido nucleico isolado, vetor, célula hospedeira, processo de produção de um anticorpo, proteína do receptor de antígeno quimérico (car), célula modificada, método para tratar ou melhorar o efeito de um câncer em um sujeito, método para potencializar a ativação de células t em um sujeito e método para modular o fenótipo de macrófagos m2a em um sujeito | |
| CL2012002662A1 (es) | Anticuerpos bivalentes biespecificos anti-veg y un segundo sitio de unión a antígeno que se une específicamente a ang-2 humana; composicion farmacéutica que comprende dicho anticuerpo; método de tratamiento de un paciente que sufre cancer; acido nucleico codificante de dicho anticuerpo, vector de expresión y célula huesped que contiene dicho ácido nucleico. | |
| BR112017005110A2 (pt) | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. | |
| BR122020002402B8 (pt) | Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
| CL2022000096A1 (es) | Anticuerpos anti-tigit y aplicación de los mismos | |
| BR112023021297A2 (pt) | Anticorpos anti-cd122 e usos dos mesmos | |
| CL2021001704A1 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| MX2024014591A (es) | Anticuerpo anti-bdca2 y uso del mismo | |
| BR112021026309A2 (pt) | Anticorpos para ativação de células t | |
| BR112019002258A2 (pt) | anticorpo que se liga a pd-1 ou fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenir ou tratar câncer | |
| CL2022003296A1 (es) | Anticuerpos anti-cd200r1 y métodos de uso de los mismos |